PMID- 29623622
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240326
IS  - 2509-4254 (Electronic)
IS  - 2509-4262 (Print)
IS  - 2509-4262 (Linking)
VI  - 2
IP  - 2
DP  - 2018 Jun
TI  - Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database 
      Analysis.
PG  - 209-219
LID - 10.1007/s41669-017-0050-3 [doi]
AB  - OBJECTIVES: Our objects was to estimate the direct healthcare costs of type 2 
      diabetes mellitus (T2DM) in France in 2013. METHODS: Data were drawn from a 
      random sample of  approximately 600,000 patients registered in the French national health 
      insurances database, which covers 90% of the French population. An algorithm was 
      used to select patients with T2DM. Direct healthcare costs from a collective 
      perspective were derived from the database and compared with those from a control 
      group to estimate the cost of diabetes and related comorbidities. Overall direct 
      costs were also compared according to the diabetes therapies used throughout the 
      year 2013. RESULTS: Cost analysis was available for a sample of 25,987 patients 
      with T2DM (mean age 67.5 +/- standard deviation 12.5; 53.9% male) matched with a 
      control group of 76,406 individuals without diabetes. Overall per patient per 
      year medical expenditures were euro6506 +/- 10,106 in the T2DM group as compared with 
      euro3668 +/- 6954 in the control group. The cost difference between the two groups was 
      euro2838 per patient per year, mainly due to hospitalizations, medication and 
      nursing care costs. Total per capita annual costs were lowest for patients 
      receiving metformin monotherapy (euro4153 +/- 6170) and highest for those receiving 
      insulin (euro12,890). However, apart from patients receiving insulin, costs did not 
      differ markedly across the different oral treatment patterns. CONCLUSION: 
      Extrapolating these results to the whole T2DM population in France, total direct 
      costs of diagnosed T2DM in 2013 was estimated at over euro8.5 billion. This estimate 
      highlights the substantial economic burden of this condition on society.
FAU - Charbonnel, Bernard
AU  - Charbonnel B
AD  - Hotel Dieu Hospital, Nantes, France.
FAU - Simon, Dominique
AU  - Simon D
AD  - Diabetes Department and ICAN (Institute of Cardiometabolism And Nutrition), Pitie 
      Hospital, Paris, France.
FAU - Dallongeville, Jean
AU  - Dallongeville J
AD  - INSERM-U1167, Lille, France.
FAU - Bureau, Isabelle
AU  - Bureau I
AD  - Cemka-Eval, 43 Bd du Marechal Joffre, 92 340, Bourg-la-Reine, France.
FAU - Dejager, Sylvie
AU  - Dejager S
AD  - Merck Sharpe & Dohme, Courbevoie, France.
FAU - Levy-Bachelot, Laurie
AU  - Levy-Bachelot L
AD  - Merck Sharpe & Dohme, Courbevoie, France.
FAU - Gourmelen, Julie
AU  - Gourmelen J
AD  - INSERM UMS 011, Villejuif, France.
FAU - Detournay, Bruno
AU  - Detournay B
AD  - Cemka-Eval, 43 Bd du Marechal Joffre, 92 340, Bourg-la-Reine, France. 
      Bruno.detournay@cemka.fr.
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Pharmacoecon Open
JT  - PharmacoEconomics - open
JID - 101700780
PMC - PMC5972121
COIS- DATA AVAILABILITY STATEMENT: Data that supported these analyses are available 
      from Dr. Bruno Detournay. FUNDING: MSD France provided funding for this project. 
      CONFLICT OF INTEREST: IB and BD are employed by Cemka-Eval, a contract research 
      organisation that was contracted by MSD France for this study. BD has also 
      received honoraria for consultancy from MSD, Novo-Nordisk, Sanofi. LLB and SD are 
      employed by MSD France. BC, DS and JD have received honoraria from MSD France for 
      participating on the scientific board for this study. BC has also received 
      honoraria for consultancy from AstraZeneca, Boehringer-Ingelheim, Janssen 
      Pharmaceuticals, Eli Lilly, MSD, Novartis, Novo-Nordisk and Sanofi. DS has served 
      as an expert for Sanofi Aventis and Takeda and has been a member of a board for 
      Astellas, MSD and Novartis, and received fees for all these activities. JG has no 
      conflicts of interest.
EDAT- 2018/04/07 06:00
MHDA- 2018/04/07 06:01
PMCR- 2017/08/07
CRDT- 2018/04/07 06:00
PHST- 2018/04/07 06:00 [pubmed]
PHST- 2018/04/07 06:01 [medline]
PHST- 2018/04/07 06:00 [entrez]
PHST- 2017/08/07 00:00 [pmc-release]
AID - 10.1007/s41669-017-0050-3 [pii]
AID - 50 [pii]
AID - 10.1007/s41669-017-0050-3 [doi]
PST - ppublish
SO  - Pharmacoecon Open. 2018 Jun;2(2):209-219. doi: 10.1007/s41669-017-0050-3.